Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05294978 · ClinicalTrials.gov registry record
EyeConic: Qualification for Cone-Optogenetics
A clinical trial of Retinal Dystrophies, sponsored by Institute of Molecular and Clinical Ophthalmology Basel.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 9
- Study locations
NCT05294978 is a study of Retinal Dystrophies that is actively recruiting participants, run by Institute of Molecular and Clinical Ophthalmology Basel. The registered enrollment target is 1,000 participants, above the 37-participant average among 10 other Retinal Dystrophies trials with a reported enrollment target (2603% higher). The trial reports 9 study locations across 4 states.
The verdict
NCT05294978, a study of Retinal Dystrophies, is actively recruiting participants, sponsored by Institute of Molecular and Clinical Ophthalmology Basel.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Optical coherence tomography (OCT)
Study Locations (9)
Other
- Beijing Institute of Ophthalmology - Beijing
- Universitätsklinikum Tübingen Augenklinik - Tübingen
- Semmelweis University, Department of Ophthalmology - Budapest
- Oculista Ospedale Parma - Parma
- University Hospital Basel, Eye Clinic - Basel
- Moorfields Eye Hospital - London
California
- University of California San Francisco, Department of Ophthalmology - San Francisco
Florida
- Bascom Palmer Eye Institute - Miami
Pennsylvania
- University of Pittsburgh, Department of Ophthalmology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05294978
The ClinicalTrials.gov registry entry for NCT05294978 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 37-participant average among 10 other Retinal Dystrophies trials with a reported enrollment target (2603% higher). The listed sponsor is Institute of Molecular and Clinical Ophthalmology Basel, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinal Dystrophies appearing as the primary indexed condition, and to 1 intervention - of which Optical coherence tomography (OCT) is the first listed.
NCT05294978 reports 9 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05294978 about?
NCT05294978 is a clinical study titled "EyeConic: Qualification for Cone-Optogenetics". This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
What is the current status of trial NCT05294978?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-07-01. Estimated completion is 2026-12.
What conditions does trial NCT05294978 study?
This clinical trial studies the following conditions: Retinal Dystrophies.
What interventions are being tested in trial NCT05294978?
The interventions under investigation include: Optical coherence tomography (OCT) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05294978?
This trial is sponsored by Institute of Molecular and Clinical Ophthalmology Basel, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05294978 being conducted?
This trial has 9 study locations across California, Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Dystrophies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
RECRUITING · Phase 1
-
SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)
RECRUITING · NA
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
RECRUITING · Phase 1
-
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.